Exhibit 107
Calculation of Filing Fee Tables
424(b)(5)
(Form Type)
Kymera Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
Security Type | Security Class Title | Fee Calculation or Fee Carry Forward Rule | Amount Registered | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee(1) | Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward | ||||||||||
Newly Registered Securities | ||||||||||||||||||
Fees to Be Paid | Equity | Common Stock, $0.0001 per share | 457(r) | 12,524,752(2) | $25.25 | $316,249,988 | 0.00014760 | $46,678.50 | ||||||||||
Fees to Be Paid | Equity | Pre-funded warrants to purchase common stock | 457(r) | 8,640,594 | $25.25(3) | – (3) | 0.00014760 | – (3) | ||||||||||
Fees Previously Paid | – | – | – | – | – | – | – | – | ||||||||||
Carry Forward Securities | ||||||||||||||||||
Carry Forward Securities | – | – | – | – | – | – | – | – | – | |||||||||
Total Offering Amounts | $316,249,988 | $46,678.50 | ||||||||||||||||
Total Fees Previously Paid | – | |||||||||||||||||
Total Fee Offsets | – | |||||||||||||||||
Net Fee Due | $46,678.50 |
(1) | Calculated in accordance with Rule 457(r) under the Securities Act of 1933, as amended (the “Securities Act”). The fee payable in connection with the offering pursuant to this prospectus supplement has been paid in accordance with Rule 456(b) under the Securities Act, and represents deferred payment of the registration fees in connection with the registrant’s Registration Statement on Form S-3ASR (Registration No. 333-259955). |
(2) | Includes 1,633,663 shares of common stock that the underwriters have an option to purchase and 8,640,594 shares of common stock that are issuable upon the exercise of the pre-funded warrants referenced below. |
(3) | Represents the sum of the pre-funded warrants sales price of $25.2499 per pre-funded warrant and the exercise price of $0.0001 per share issuable pursuant to the pre-funded warrants. Pursuant to Securities and Exchange Commission staff interpretation, the entire fee is allocated to the common stock underlying the pre-funded warrants. |